Dr David J. Pinato is a distinguished Clinician Scientist and Medical Oncologist at Imperial College London, renowned for his groundbreaking contributions to the field of hepatocellular carcinoma (HCC). As Director of Developmental Cancer Therapeutics, Dr Pinato spearheads transformative research in the early detection, management, and treatment of liver cancer. His pioneering work in integrating novel biomarkers into clinical practice has reshaped HCC monitoring and surveillance strategies, significantly improving patient outcomes.
Dr Pinato’s expertise extends to advancing immunotherapy for HCC, where he explores innovative therapeutic combinations to enhance efficacy and overcome resistance. His prolific research output includes high-impact publications in leading medical journals, establishing him as a thought leader in translational oncology.
In recognition of his significant achievements, Dr Pinato was honoured with the prestigious EASL Emerging Leader Award in 2023. His clinical insights and visionary leadership continue to drive innovation in HCC care on a global scale.